An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation

[1]  Y. Wen,et al.  Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. , 2013, Journal of hepatology.

[2]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[3]  J. Hampe,et al.  Hepatitis B virus–induced lipid alterations contribute to natural killer T cell–dependent protective immunity , 2012, Nature Medicine.

[4]  M. Heikenwalder,et al.  Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. , 2012, Gastroenterology.

[5]  Yanning Liu,et al.  Blockade of Tim‐3 signaling restores the virus‐specific CD8+ T‐cell response in patients with chronic hepatitis B , 2012, European journal of immunology.

[6]  F. Zoulim,et al.  Selection of chronic hepatitis B therapy with high barrier to resistance. , 2012, The Lancet. Infectious diseases.

[7]  Percy A. Knolle,et al.  Living in the liver: hepatic infections , 2012, Nature Reviews Immunology.

[8]  U. Protzer,et al.  Design of therapeutic vaccines: hepatitis B as an example , 2012, Microbial biotechnology.

[9]  B. Fox,et al.  Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy , 2011, Clinical Cancer Research.

[10]  Fabien Zoulim,et al.  Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. , 2011, Journal of hepatology.

[11]  Jun Jiao,et al.  Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response , 2011, Nature nanotechnology.

[12]  B. Fox,et al.  Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism , 2011, Clinical Cancer Research.

[13]  Qiang Deng,et al.  Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. , 2011, Journal of hepatology.

[14]  H. Whittle,et al.  Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection , 2011, PloS one.

[15]  M. Mondelli,et al.  Natural killer cells in viral hepatitis: facts and controversies , 2010, European journal of clinical investigation.

[16]  F. Chisari,et al.  Immune effectors required for hepatitis B virus clearance , 2009, Proceedings of the National Academy of Sciences.

[17]  B. Fox,et al.  Cross-presentation of tumor associated antigens through tumor-derived autophagosomes , 2009, Autophagy.

[18]  M. Ghany,et al.  Antiviral resistance and hepatitis B therapy , 2009, Hepatology.

[19]  R. Fontana.  Side effects of long‐term oral antiviral therapy for hepatitis B , 2009, Hepatology.

[20]  V. Crotzer,et al.  Autophagy and Its Role in MHC-Mediated Antigen Presentation1 , 2009, The Journal of Immunology.

[21]  M. Massari,et al.  Early kinetics of innate and adaptive immune responses during hepatitis B virus infection , 2009, Gut.

[22]  W. Urba,et al.  Efficient cross-presentation depends on autophagy in tumor cells. , 2008, Cancer research.

[23]  B. Ahn,et al.  Ubiquitin-dependent and -independent proteasomal degradation of hepatitis B virus X protein. , 2008, Biochemical and biophysical research communications.

[24]  G. Lau,et al.  Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. , 2007, Vaccine.

[25]  Ding‐Shinn Chen,et al.  An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection , 2006, Proceedings of the National Academy of Sciences.

[26]  T. Yoshimori.  Autophagy: a regulated bulk degradation process inside cells. , 2004, Biochemical and biophysical research communications.

[27]  R. Purcell,et al.  CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection , 2003, Journal of Virology.

[28]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[29]  L. Siracusa,et al.  Hepatitis B virus transgenic mouse model of chronic liver disease , 1999, Nature Medicine.

[30]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.

[31]  U. Spengler,et al.  Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. , 1991, Journal of hepatology.

[32]  A Valli,et al.  Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. , 1990, Journal of immunology.

[33]  G. Acs,et al.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Koblin,et al.  Hepatitis B virus infection. , 1998, The New England journal of medicine.